Please assess the completion status of the following clinical trial:

Trial Title: The Use of Proton Pump Inhibitor on the Prevention of Gastric Cancer Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven primary gastric adenocarcinoma~* Age ≥18 years~* Plan for 1st line or 2nd line palliative chemotherapy~* Cancer staging: metastatic (TxNxM1) or locally advanced unresectable gastric cancer (T4NxMx with unresectable), or T2-3NxMx with inoperable condition~* Performance status (PS) of 0 to 2 on Eastern Cooperative Oncology Group (ECOG) scale~* Adequate organ functions defined as indicated below: (a) WBC \> 3000/mm3, (b) Hb 9.0 g/dL regardless of any transfusion history, (c) Platelet ≥100,000/mm3, (d) AST/ALT ≤ 2.5 x UNL (≤ 5 x UNL if liver metastases are present) (e) Total bilirubin ≤1.5x UNL (f) Cr ≤1.5 x UNL~* Written informed consent~Exclusion Criteria:~* Other malignancy within the past 3 years except adequately treated non-melanomatous skin cancer or carcinoma in situ of the cervix~* Patients with significant or uncontrolled gastrointestinal bleeding in the past two weeks without evidence of resolution documented by endoscopy or colonoscopy~* Previous subtotal gastrectomy or total gastrectomy~* Patient with a plan for neo-adjuvant chemotherapy~* Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome, or inability to take oral medication~* Allergy history to proton pump inhibitor~* Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy~* Inadequate cardiovascular function: (a) New York Heart Association class III or IV heart disease, (b) Unstable angina or myocardial infarction within the past 6 months, (c) History of significant ventricular arrhythmia requiring medication with antiarrhythmics or significant conduction system abnormality~* Requirement for therapeutic anticoagulant therapy, aspirin or non-steroidal anti-inflammatory agents except COX-2 selective inhibitor~* Requirement for therapeutic corticosteroid; the use of dexamethasone as anti-emetics or a premedication of chemotherapy-associated hypersensitivity is not an exclusion criteria~* Need for PPI maintenance treatment for uncontrolled reflux esophagitis or active peptic ulcer~* Psychiatric disorder that would preclude compliance~* Pregnant or breast-feeding women~* Untreated folate or vitamine B12 deficiency anemia~* Bone marrow metastasis, or evidence of microangiopathic hemolytic anemia (MAHA)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: ACTIVE_COMPARATOR): Proton pump inhibitor (lansoprazole) therapy for the prevention of gastric cancer bleeding
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo for the prevention of gastric cancer bleeding

Based on this trial design, predict the completion outcome and termination type (if applicable).